Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146972
Max Phase: Preclinical
Molecular Formula: C74H110N14O10
Molecular Weight: 1355.78
Molecule Type: Small molecule
Associated Items:
ID: ALA2146972
Max Phase: Preclinical
Molecular Formula: C74H110N14O10
Molecular Weight: 1355.78
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NCCC[C@@H]1NC(=O)[C@H](CC23CC4CC(CC(C4)C2)C3)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CC23CC4CC(CC(C4)C2)C3)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC1=O
Standard InChI: InChI=1S/C74H110N14O10/c75-23-7-17-53-63(89)83-57(35-45-13-3-1-4-14-45)71(97)87-27-11-21-61(87)69(95)81-55(19-9-25-77)65(91)86-60(44-74-40-50-32-51(41-74)34-52(33-50)42-74)68(94)80-54(18-8-24-76)64(90)84-58(36-46-15-5-2-6-16-46)72(98)88-28-12-22-62(88)70(96)82-56(20-10-26-78)66(92)85-59(67(93)79-53)43-73-37-47-29-48(38-73)31-49(30-47)39-73/h1-6,13-16,47-62H,7-12,17-44,75-78H2,(H,79,93)(H,80,94)(H,81,95)(H,82,96)(H,83,89)(H,84,90)(H,85,92)(H,86,91)/t47?,48?,49?,50?,51?,52?,53-,54-,55-,56-,57+,58+,59-,60-,61-,62-,73?,74?/m0/s1
Standard InChI Key: QVCKFPUPDMOCKJ-JJIWIEPSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1355.78 | Molecular Weight (Monoisotopic): 1354.8529 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):